Trial Profile
A Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Single Agent Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With Relapsed Refractory Classical Hodgkin's Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 12 Sep 2023 Planned End Date changed from 1 Sep 2023 to 18 Aug 2024.
- 06 Oct 2021 Planned End Date changed from 1 Sep 2021 to 1 Sep 2023.
- 06 Oct 2021 Planned primary completion date changed from 1 Sep 2021 to 1 Sep 2023.